Morgan Stanley Maintains Overweight on MetLife, Lowers Price Target to $85
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Nigel Dally maintains an Overweight rating on MetLife (NYSE:MET) but lowers the price target from $86 to $85.
August 19, 2024 | 5:12 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has maintained its Overweight rating on MetLife but slightly reduced the price target from $86 to $85, indicating a minor adjustment in expectations.
The Overweight rating suggests continued confidence in MetLife's performance, but the slight reduction in the price target indicates a minor adjustment in expectations. This is likely to have a neutral short-term impact on the stock price as the overall sentiment remains positive.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100